License Purchase Price. The Licensee shall pay to Optimo a non-refundable license purchase price. The applicable purchase prices are set out on Optimo’s Website. Optimo reserves its rights to amend the license purchase prices at any time without notice. T F No refund on the license purchase price will occur if the number of Licensed Units and/or the number of Specified License Uses specified in the Order is eventually reduced or if you decide to discontinue, in whole or in part, the use of the Licensed Fonts.
License Purchase Price. Within three (3) business days following the execution and delivery of this Agreement (time being of the essence), Licensee shall pay to Licensor the sum of Two Million Five Hundred Thousand ($2,500,000) Dollars by certified or bank check or wire transfer of immediately available funds to Licensor's bank account.
License Purchase Price. In exchange for the license granted in Section 2.1 hereof and the Option, Q Bio shall:
(a) issue to BNI - 110,000 shares of its common stock (the “Stock Payment”) pursuant to the following schedule:
(i) 50,000 shares of Q Bio common stock upon Closing (the “Initial Stock Payment”);
(ii) shares of Q Bio common stock upon successful amendment of ANDA 75-941Market Authorization License granted to BNI on January 6, 2003 by the FDA (a copy of which license is attached hereto as Exhibit 3.2(a)(ii) to allow Isotex or another properly licensed entity to manufacture Strontium Chloride Sr89 Injection, USP (the “Amended FDA Market Authorization License”), provided that if such amendment occurs after the Amended Market Authorization Deadline such amount shall be reduced to **** shares (“Market Authorization Stock Payment”); and
(iii) shares of Q Bio common stock upon the First Sale, provided that if the Amended FDA Market Authorization License is approved by the U.S. FDA after the Amended Market Authorization Deadline such amount shall be reduced to **** shares (“First Sale Payment”). From the time each of the Initial Stock Payment, Market Authorization Stock Payment and First Sale Payment are issued, the shares of common stock underlying each issuance shall be held in escrow at SOVR Law and restricted from transfer pursuant to the terms of a lock-up agreement, the form of which shall be delivered within ten business (10) days of Closing (the “Lock-Up Agreement”).
(b) subject to the terms ultimately agreed to between BNI and the holders of the liens found in Exhibit 7.3 hereto, pay $850,000 to be used in the final steps to acquire BNI Asset and commercialize a BNI Product in accordance with the use of proceeds found in Schedule 3.2(b) (“Total Cash Investment”). Of the Total Cash Investment Q Bio shall transfer:
(i) $**** to BNI at Closing directly to BNI (the “Initial Cash Payment”) (ii) $**** to BNI no later than 30 days from Closing to third parties approved in writing by BNI that are preparing or supporting the preparation of the Amended FDA Market Authorization License and/or to undertaking studies or other actions necessary to complete such Amended FDA Market Authorization License; and
(iii) the remaining $**** Total Cash Investment in accordance with a timeline to be mutually agreed upon between the Parties, but in no event longer than 12 months from the Closing; provided that prior to the approval of the Amended FDA Market Authorization License by the FDA such ...
License Purchase Price. 1 2.3 CLOSING.....................................................1 2.4
License Purchase Price. 3.1 Licensee will issue 5 million shares of its common stock (the “Shares”) to the Licensor for the purchase from the Licensor the exclusive license rights to the products, subject to the License Exception, in accordance with the terms and conditions of this Agreement.
3.2 The Shares are due upon execution of this Agreement and their delivery shall be completed no later than the Completion Date and subject to the terms and conditions of this agreement.
License Purchase Price. 3.1 Licensee will pay $50,000 (the “License Fee”) to the Licensor for the purchase from the Licensor of the exclusive license rights to the Licensed Products, subject to the License Exception, in accordance with the terms and conditions of this agreement.
3.2 The License Fee is due upon execution of this agreement subject to the terms and conditions of this agreement and is payable as follows:
a. $10,000 payable within seven days after the Effective Date;
b. an additional $15,000 payable within 30 days after the Effective Date; and
c. a final payment of $25,000 payable within 90 days after the Effective Date.
License Purchase Price. 5 2.3 closing..................................................................................5 2.4
License Purchase Price. At the Closing, Vidor and Newco each shall wire transfer its respective portion of the License Purchase Price in the manner and to the account of the Company specified in Section 2.3.
License Purchase Price. In consideration for the licenses and rights granted to Licensee under this Agreement, Licensee shall pay to Licensor the License Purchase Price in the manner and amounts set forth Exhibit B, which payments will be nonrefundable and irrevocable except as otherwise expressly provided herein.
License Purchase Price. In consideration of the license granted hereunder, Licensee shall pay to Licensor, by federal bank wire, certified check or cashier’s check, a total of Four Million Seven Hundred Fifty Thousand and No/100 Dollars ($4,750,000.00) (the “Licensee Purchase Price”), payable as follows:
